Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    valganciclovir pulmonary fibrosis
Previous Study | Return to List | Next Study

A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02871401
Recruitment Status : Completed
First Posted : August 18, 2016
Results First Posted : April 29, 2022
Last Update Posted : April 29, 2022
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Jonathan Kropski, Vanderbilt University

Brief Summary:
The investigators will conduct a single-center, prospective, randomized, placebo-controlled, double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary fibrosis (IPF). Patients with mild, moderate or severe IPF with serologic evidence of current or past Epstein-Barr Virus (EBV) or cytomegalovirus (CMV) infection. Randomization will be to pirfenidone plus placebo or pirfenidone plus valganciclovir. Thirty subjects will be enrolled and randomized to treatment with pirfenidone plus valganciclovir (20 subjects) or pirfenidone plus placebo (10 subjects) for 12 weeks. The primary outcome will be safety and tolerability will be determined by type, frequency and duration of adverse events (AEs) and serious adverse events (SAEs) after 12 weeks of study drug treatment. All study subjects will be offered bronchoscopy with bronchoalveolar lavage (BAL) at study initiation and upon completion of treatment (12 weeks). Subjects will then be followed up at routine clinic visits at 6, 9 and 12 months for data collection.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: Valganciclovir Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Actual Study Start Date : January 3, 2018
Actual Primary Completion Date : January 31, 2020
Actual Study Completion Date : January 31, 2020


Arm Intervention/treatment
Experimental: Valganciclovir
Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
Drug: Valganciclovir
Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
Other Name: Valcyte

Placebo Comparator: Placebo
Placebo, 2 pills by mouth one time per day x 12 weeks
Drug: Placebo
Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.




Primary Outcome Measures :
  1. Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events [ Time Frame: 12 weeks ]
    Proportion of study subjects who discontinue study drug due to adverse events


Secondary Outcome Measures :
  1. Adverse Events - Number [ Time Frame: 12 weeks ]
    Number of subjects with each reported adverse event

  2. Serious Adverse Events [ Time Frame: 12 weeks ]
    Number of subjects with each serious adverse event

  3. Total # Adverse Events [ Time Frame: Randomization to 16 weeks ]
    Total number of adverse events


Other Outcome Measures:
  1. Change in Forced Vital Capacity (FVC) [ Time Frame: Baseline vs. 12 weeks, 1 year ]
    Change in FVC percent predicted compared to baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. age >21 and <80 years
  2. ability to provided informed consent
  3. diagnosis of probable or definite IPF according to American Thoracic Society (ATS) criteria
  4. tolerance of full-dose (2403 mg/day) pirfenidone
  5. Positive serology for EBV or CMV

Exclusion Criteria:

  1. FVC < 40% predicted
  2. Diffusing capacity for carbon monoxide (DLCO) < 35% predicted (Crapo)
  3. Forced expiratory volume (FEV)1/FVC <0.7
  4. Significant centrilobular emphysema (>40% by HRCT)
  5. Active tobacco use (cigarette or cigar smoking)
  6. Resting oxygen saturation (SpO2) on room air <89%
  7. Listed for lung transplantation defined as being assigned a lung allocation score
  8. environmental exposure (occupational, environmental, drug, etc.) felt by the principal investigator (PI) to be the etiology of the interstitial disease
  9. diagnosis of collagen-vascular conditions (according to the published American College of Rheumatology criteria)
  10. history of unstable or deteriorating cardiac disease
  11. acute coronary syndrome, coronary artery bypass, or angioplasty within 3 months of screening
  12. uncontrolled arrhythmia
  13. uncontrolled hypertension
  14. known HIV or hepatitis C
  15. known cirrhosis or chronic active hepatitis
  16. active substance or alcohol abuse
  17. pregnancy or lactation
  18. Women of childbearing potential who are not using a medically approved means of contraception. Subjects will be considered of childbearing potential if they are not surgically sterile or have not been postmenopausal for at least 2 years [any subject who is postmenopausal for < 2 years will be required to have a follicle-stimulating hormone (FSH) level to assess her potential to become pregnant
  19. clinically relevant lab abnormalities (obtained within 30 days before enrollment), including:

    1. creatinine > 2 x upper limit of normal (ULN)
    2. hematology outside of specified limits: white blood cells (WBCs) < 3,500/mm3; hematocrit < 25% or > 59%; platelets < 100,000/mm3;
    3. total bilirubin > 2 x ULN
    4. Aspartate (AST) or alanine aminotransferases (ALT)/ serum glutamic-oxaloacetic; transaminase (SGOT), or serum glutamic pyruvic transaminase (SGPT) > 2.0 x ULN
    5. alkaline phosphatase > 3 x ULN
    6. albumin < 3.0 mg/dL at screening
  20. known hypersensitivity to study medication
  21. any condition that, in the judgment of the PI, might cause participation in this study to be detrimental to the subject or that the PI deems makes the subject a poor candidate
  22. any therapy with immunosuppressants such as prednisone, azathioprine, or mycophenolate currently or anticipated to be needed during the study period (subjects on these drugs prior to the study will require a 30-day washout period before randomization)
  23. participation in another IPF clinical treatment trial during the study period (if completing another IPF clinical treatment trial, then a 30-day washout period is required before randomization)
  24. requirement for chronic suppressive therapy with valacyclovir for recurrent herpes virus infection
  25. History of myelodysplasia, aplastic anemia, refractory anemia, or multiple myeloma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02871401


Locations
Layout table for location information
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University Medical Center
Genentech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jonathan A Kropski, MD Vanderbilt University Medical Center
  Study Documents (Full-Text)

Documents provided by Jonathan Kropski, Vanderbilt University:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jonathan Kropski, Assistant Professor of Medicine, Vanderbilt University
ClinicalTrials.gov Identifier: NCT02871401    
Other Study ID Numbers: 160693
First Posted: August 18, 2016    Key Record Dates
Results First Posted: April 29, 2022
Last Update Posted: April 29, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jonathan Kropski, Vanderbilt University:
IPF
Herpesvirus
Valganciclovir
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Valganciclovir
Antiviral Agents
Anti-Infective Agents